BBLG übertreffen die 12 der letzten 15Schätzungen.
80%
Nächster Bericht
Datum des nächsten Berichts
24. Feb. 2026
Estimate forQ4 25(Revenue/ EPS)
--
/
-$0.34
Implizierte Änderung vonQ3 25(Revenue/ EPS)
--
/
-8.11%
Implizierte Änderung vonQ4 24(Revenue/ EPS)
--
/
-90.76%
Bone Biologics Corp Common Stock earnings per share and revenue
On 14. Nov. 2025, BBLG reported earnings of -0.37 USD per share (EPS) for Q3 25, beating the estimate of -1.25 USD, resulting in a 70.51% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +1.69% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 3 analysts forecast an EPS of -0.34 USD, with revenue projected to reach -- USD, implying an decrease of -8.11% EPS, and increase of 0.00% in Revenue from the last quarter.
FAQ
What were Bone Biologics Corp Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Bone Biologics Corp Common Stock reported EPS of -$0.37, beating estimates by 70.51%, and revenue of $0.00, 0% as expectations.
How did the market react to Bone Biologics Corp Common Stock's Q3 2025 earnings?
The stock price moved up 1.69%, changed from $1.60 before the earnings release to $1.63 the day after.
When is Bone Biologics Corp Common Stock expected to report next?
The next earning report is scheduled for 24. Feb. 2026.
What are the forecasts for Bone Biologics Corp Common Stock's next earnings report?
Based on 3
analysts, Bone Biologics Corp Common Stock is expected to report EPS of -$0.34 and revenue of -- for Q4 2025.